Cisapride (removed from Market 2000)

Cardiovascular

• Serious cardiac arrhythmias including ventricular tachycardia, ventricular fibrillaton, torsades de pointes, and QT prolongation.
• Risk factors include concurrent therapy with drugs known to cause QT prolongation, depleted serum electrolytes.

Drug Interactions

• Contraindicated with numerous drugs including those known to cause QT prolongation (tricyclics, certain antipsychotics) or CYP 450 3A4 inhibitors (fluconazole, ketoconazole, itraconazole).
• See package insert
• Do not exceed recommended doses

Note:  This drug was withdrawn from market in 2000 and only available via restricted distribution.

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

• Perform 12 ECG lead prior to administration
• Do not initiate therapy if QTc > 450 msec
• Serum electrolytes and creatinine assessed prior to therapy and whenever condition develops that may affect electrolyte balance or renal function.
• If syncope, rapid or irregular heartbeat develops stop drug.
• Drug withdrawn in 2000 and is available only via restricted distribution and registration program

Patient Counseling Information

• Propulsid

Medication Guides

Patient Medication Guide

Package Inserts

Cisapride

Additional Information

• Cardiovascular
• Drug Interactions